• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SNT
Click for more information
0.00% 1.9¢

SYNTARA LIMITED - Charts / Financials

Market Cap $22.68M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 12.34pm 24/05/2024 (20 minute delay) ?
Day
Open 2.0¢   Day High 2.0¢   Day Low 1.9¢
Daily Volume 1574466
Bids   Sellers
Number Price Volume   Number Price Volume
4 1.9¢ 784821   5 2.0¢ 1080275

Directors & Senior Management

Mr. Gary Jonathan Phillips Chief Executive Officer, Managing Director, Executive Director
Mr. David Morris Mcgarvey Chief Financial Officer, Company Secretary
Dr. Jana Baskar Chief Medical Officer
Mr. Wolfgang G. Jarolimek Head - Drug Discovery
Ms. Kristen Morgan Alliance Management and Head - Medical and Regulatory Affairs
Dr. Kathleen Mary Metters Non-Executive Chairman of the Board
Mr. Waradana Malitha Hashan De Silva Non-Executive Director
Dr. Simon P. Green Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
1.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $22.68M
Open High Low Value Volume
2.0¢ 2.0¢ 1.9¢ $30.01K 1.574M

Buyers (Bids)

No. Vol. Price($)
4 784821 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 1080275 5
View Market Depth
Last trade - 12.35pm 24/05/2024 (20 minute delay) ?
Last
1.9¢ 		  Change
0.000 ( 5.00 %)
Open High Low Volume
2.0¢ 2.0¢ 1.9¢ 35000
Last updated 12.34pm 24/05/2024 ?

Top Stories

AIC Mines raises $57m to extend Eloise copper mine lifecycle

AIC Mines has raised $57 million to extend the life of the Eloise copper-gold mine in North Queensland.
Yandal lines up prime gold targets at Ironstone Well-Barwidgee Yandal Resources Ltd is set to begin diamond drilling at its Ironstone Well-Barwidgee Gold Project to test a number of targets.
The Telstra twist - What the job cuts decision mean for investors? Telstra (ASX:TLS) made headlines last week by announcing significant job cuts of up to 2,800 positions as part of cost-saving measures. This decision resulted in one of the largest weekly declines in its share price since 2020 and raised questions about whether this presents an opportunity to acq...
Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW Talisman Mining Ltd has extended the system at its Rip n Tear prospect in New South Wales with diamond drilling.
Nimy seeks massive sulphide systems through surveying at WA prospects Nimy Resources has begun a series of geophysical surveys and says it has discovered a 3,004km2 greenstone belt in Western Australia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.